Show/hide main menu

News

News Highlights

Collaboration to Advance Tissue-derived gamma delta (γδ) T Cells

Posted on 10/05/2017
crick

Takeda and GammaDelta Therapeutics Announce Collaboration to Advance Tissue-derived gamma delta (γδ) T Cells

‘The pioneering research developed by Professor Adrian Hayday and Dr. Oliver Nussbaumer at King’s College London and the Francis Crick Institute, the scientific founders of our company, forms the basis for the development of potentially transformational treatments for cancer and autoinflammatory diseases,’ said Dr Paolo Paoletti, MD, CEO of GammaDelta Therapeutics. ‘We believe the collaboration with Takeda validates our novel approach and should allow us to move rapidly to the clinic.’ Patents filed by King’s College London were licensed to GammaDelta Therapeutics during the company’s initial spin-out.

Takeda, together with Abingworth, will commit up to $100 million in funding to accelerate GammaDelta Therapeutics led Research and Development. The funding includes an equity investment, an option fee and research and development funding, and provides Takeda the exclusive right to purchase GammaDelta Therapeutics. Under the agreement, Takeda will appoint a director to GammaDelta Therapeutics’ board.

‘At Takeda, we recognize the enormous potential of tissue resident γδ T cells to deliver transformative medicines in our core therapeutic areas of oncology and gastroenterology,’ said Daniel Curran, MD, Head of the Center for External Innovation, Takeda. ‘This collaboration is another example of our strategy to invest in highly innovative areas of science and we’re pleased to collaborate with the experienced team at GammaDelta Therapeutics as they aim to take a leadership position in this rapidly emerging field.’

‘We are delighted by the progress GammaDelta Therapeutics has made since we founded the company in 2016,’ said Tim Haines, Managing Partner at Abingworth and a Director at GammaDelta Therapeutics. ‘This collaboration with Takeda will enable the company to advance the development of this exciting technology, which has the potential to address significant unmet needs in cancer and autoinflammatory diseases.’

‘This strategic collaboration is an exciting investment into a company that has its roots at King’s College London. Professor Hayday’s and Dr. Nussbaumer’s research upon which GammaDelta Therapeutics is based was undertaken at King’s College London as well as the Francis Crick Institute with funding obtained from various funding bodies, including Cancer Research UK and the Biomedical Research Centre.  It’s gratifying to see that GammaDelta Therapeutics have managed to secure such strong investment to accelerate their R&D and enable this technology to develop into potentially transformative medicines,’ Dr Mike Shaw, Director of IP & Licensing, King’s College London.

Takeda signed certain of the agreements with GammaDelta Therapeutics through its wholly-owned subsidiary, Millennium Pharmaceuticals, Inc.

 

For further information, please contact the Public Relations Department on 0207 848 3202 or pr@kcl.ac.uk  

Rss Feed Atom Feed

News Highlights:

News Highlights...RSS FeedAtom Feed

Vitamin D in pregnancy may help prevent childhood asthma

Vitamin D in pregnancy may help prevent childhood asthma

Description
A new study published today in the Journal of Allergy and Clinical Immunology has found that taking Vitamin D supplements in pregnancy can positively modify the immune system of the newborn baby, which could help to protect against asthma and respiratory infections, a known risk factor for developing asthma in childhood.
Researchers pinpoint how diesel fumes could cause 'flare up' of respiratory symptoms

Researchers pinpoint how diesel fumes could cause 'flare up' of respiratory symptoms

Description
Scientists have shown how diesel fumes trigger respiratory reflexes which could potentially worsen underlying conditions, such as asthma.
Palliative care increase by 2040

Palliative care increase by 2040

Description
The number of people requiring palliative care over the next 25 years is likely to increase substantially, requiring a shift in healthcare priorities in England and Wales, according to new research by King's published in the open access journal BMC Medicine.

Share this story:

 

Follow Us

@kingscollegelon

Live Twitter feed...

@kingscollegelon
Join the conversation
Sitemap Site help Terms and conditions Privacy policy Accessibility Modern slavery statement Contact us

© 2017 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454